ICYMI: The PASTEUR Act was reintroduced in the Senate. Plus, more from BIO 2026, including the latest on the 340B program and what the media was covering at the Convention. (639 words, 3 minutes, 12 ...

Day 3 of BIO 2026 looked ahead to biotech's next chapter: how AI could accelerate drug discovery, why U.S. biotechnology leadership is a national security priority, and what states can do to compete ...

John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary ...

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the ...

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented ...

House lawmakers today unveiled a new draft of the BIOSECURE Act. Shortly after, BIO President and CEO, John F. Crowley, made the following statement: "The BIOSECURE bill released in the House today ...

The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) today released new data on the bioscience industry in the United States. The new report, The U.S ...

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the resignation of FDA Commissioner Marty Makary. “Dr.

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on changes announced to the US childhood vaccine schedule.

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic ...

WASHINGTON, DC (December 2, 2025) – The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report ...

Philadelphia, PA (June 4, 2019) – The Biotechnology Innovation Organization (BIO) is pleased to announce Jeremy M. Levin, DPhil, MB BChir, Chief Executive Officer of Ovid Therapeutics, as the new ...